Pharma Journalist -

AstraZeneca’s Brilinta (ticagrelor) has been approved in the US to reduce the risk of a first heart attack or stroke in high-risk patients with coronary artery disease (CAD), the most…
Read More...

AstraZeneca and MSD Inc., Kenilworth, N.J., US announced that Lynparza (olaparib) has been recommended for marketing authorisation in the European Union (EU) for the 1st-line…
Read More...

Regeneron Pharmaceuticals, Inc. and Intellia Therapeutics, Inc. announced an expansion of their existing collaboration to provide Regeneron with rights to develop products for…
Read More...

AbbVie and Jacobio Pharmaceuticals announced a global, strategic collaboration to develop and commercialize SHP2 inhibitors, which target a key node in cancer and immune cells. SHP2 …
Read More...

Goldfinch Bio, a clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, announced the closing of an…
Read More...

Innovent Biologics, Inc. jointly announced with Eli Lilly and Company (Lilly) the research results of TYVYT (sintilimab injection) ORIENT-1 study for the treatment of relapsed or…
Read More...

Celltrion Group announced positive pre-clinical results for its COVID-19 antiviral antibody treatment, with data demonstrating a 100-fold reduction in the viral load of SARS-CoV-2, the…
Read More...

Ajinomoto Bio-Pharma Services announced that it has entered into a manufacturing agreement with Humanigen, Inc., for the fill finish supply of lenzilumab, currently being studied in a…
Read More...

Roche announced the initiation of a global phase III, randomised, double-blind, multicentre study (REMDACTA) to evaluate the safety and efficacy of Actemra/RoActemra plus the…
Read More...

Almac Group has received a $288,000 grant to support a clinical study in Sub-Saharan Africa in efforts to find a treatment for Coronavirus. This was awarded from the COVID-19…
Read More...